Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ipsen to acquire U.S.-based Epizyme for $247 million. By: MarketWatch June 27, 2022 at 02:12 AM EDT The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020 Read More >> Related Stocks: Epizyme Inc Royalty Pharma Plc Cl A Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Ipsen to acquire U.S.-based Epizyme for $247 million. By: MarketWatch June 27, 2022 at 02:12 AM EDT The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020 Read More >> Related Stocks: Epizyme Inc Royalty Pharma Plc Cl A